We studied the toxic effects of amphotericin B and gramicidin S, alone and in combination, using free and liposome-encapsulated drugs. In vitro toxic effects of the drugs on human erythrocytes and Candida albicans were determined by measuring leakage of intracellular potassium ions (K+). Liposomal formulations of both drugs greatly reduced K+ leakage from human erythrocytes, whereas liposomal gramicidin S, but not liposomal amphotericin B, prevented K+ leakage from C. albicans. In both free and liposomal forms, the combinations of drugs produced decreased toxicity to erythrocytes compared with the drugs alone. This protective effect was more apparent with liposomal combinations than with free drug combinations. A significant increase in fungal cell toxicity was observed, however, when free and liposomal drug combinations were tested against C. albicans. The results suggest that optimal concentrations of liposomal drug combinations (amphotericin B and gramicidin S) may provide increased toxicity against fungal cells and simultaneously protect mammalian cells.
Amphotericin B (AmpB) remains the drug of choice for the treatment of systemic fungal infections. However, despite its efficacy, the drug has severe side effects that are related to its interaction with the plasma membranes of mammalian cells (1, 4, 5, 8) . Liposome encapsulation of AmpB has been demonstrated to enhance the therapeutic index of the drug (7, (9) (10) (11) (12) partly by decreasing toxicity to human erythrocytes (RBC) while maintaining its in vivo antifungal efficacy (10) . Studies from our laboratory have shown that AmpB and liposomal AmpB (L-AmpB) have comparable antifungal activity in vitro against several strains of Candida albicans (7) . Antifungal activity has also been improved by using drug combinations (1, 6, 11, 13) . lonophores, including gramicidin S (GMS), are membrane-active drugs used extensively to study membrane structure and function (2, 3) . Since GMS has antifungal activity and its mechanism of action is different from that of AmpB, it was considered a candidate to be combined with Ampl3. By using this combination, the AmpB concentration could be lowered, thus reducing the AmpB-related toxicity further than the free or liposomal drug alone. GMS causes lysis of mammalian cells; liposome encapsulation decreases its RBC toxicity (lysis), and it has been found to have synergistic antifungal activity when combined with AmpB (6) . In this report we discuss the effect of various AmpB and GMS combinations on mammalian and fungal cell membranes, using leakage of intracellular potassium ions (K+) as an indicator of toxicity. Measurement of K+ released from the cells was found to be a more sensitive assay than measurement of cytolysis to detect mild impairment in the structural organization of plasma membranes.
MATERIALS AND METHODS
Drugs and lipids. Deoxycholate-free AmpB was a gift from E. R. Squibb & Sons, Princeton, N.J. GMS was purchased from Calbiochem-Behring, La Jolla, Calif. Chromatographically pure dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol were purchased from Avanti Polar Lipids, Birmingham, Ala.
Liposome preparation. Multilamellar liposomes containing AmpB or GMS were prepared as detailed previously (10, 11) . Briefly, the drugs dissolved in methanol were mixed with a chloroform solution of phospholipids (dimyristoyl phosphatidylcholine/dimyristoyl phosphatidylglycerol ratio, 7:3). Organic solvents were evaporated under vacuum with a rotary evaporator. The lipid residue was dispersed in 0.9% NaCI by shaking to form liposomes. The suspension was centrifuged at 50,000 x g for 60 min and suspended in a known volume of saline. The amount of drug encapsulated was quantitated by solubilizing the samples in methanol and measuring the A40_ and A206 of AmpB and GMS, respectively.
Preparation of cells. C. albicans 336 was inoculated into 50 ml of sterile Sabouraud dextrose broth (Scott Laboratories, Inc., Houston, Tex.) and incubated at 35°C for 18 h. The medium was centrifuged (1,700 x g for 10 min), and the pellet was washed three times with 0.9% NaCl and finally diluted with saline to a 10% suspension.
Fresh whole blood from healthy volunteers was obtained as a 50% suspension in Alsever solution and centrifuged at 800 x g for 10 min. The RBC pellet was washed three times in 0.9% NaCl, and the final packed cell volume was diluted with saline to a 10% suspension.
Assay of toxicity. Various concentrations of free or liposomal drugs were mixed with RBC or Candida cells to give a 2% final concentration of cells in each tube. All tubes were incubated in a water bath (37°C for 60 min) and centrifuged at 800 x g for 10 Fig. 1 . Free AmpB produced over 80% K+ leakage at 2.5 ,ug/ml and 97% at 10 ,ug/ml. No significant K+ release was observed at a dose of L-AmpB 10 times higher than that of the free drug (Fig. 1A) . Figure 1B shows that GMS produced 100% K+ release at 50 ,ugIml, whereas no toxicity was observed with liposomal GMS (L-GMS). Figure 2 shows the effects of free AmpB alone (dose range, 0.15 to 20 ,ug/ml), free GMS alone (0.78 to 100 ,ugIml), and combinations of a fixed dose of free AmpB (0.62 or 2.5 ,ug/ml) and various concentrations of free GMS. The combination of 0.62 ,ug of free AmpB per ml with increasing concentrations of GMS produced K+ release in the same amounts as GMS alone, whereas 2.5 jig of free AmpB per ml with GMS at 6.25-and 12.5-,ug/ml concentrations showed a protective effect, which gradually disappeared as the GMS concentration was increased. Interestingly, GMS concentrations of below 6.25 ,ug/ml did not show this protective effect with 2.5 ,ug of AmpB per ml. The combination of 2.5 ,ug of AmpB per ml and 12.5 ,ug of GMS per ml reduced the toxicity to RBC by 50% as compared with an equivalent concentration of AmpB alone.
The effects produced by L-AmpB alone (0.78 to 100 ,ug/ml), L-GMS alone (0.78 to 100 ,ug/ml), and combinations of the identical dose range of L-GMS with fixed doses (i.e., 6, 25, or 100 ,ug/ml) of L-AmpB are shown in Fig. 3 . When a low concentration of L-AmpB was used, the combined effect of L-AmpB and L-GMS was not different from that produced by L-GMS alone. However, a protective effect was produced when increasing doses of L-GMS were added to 25 or 100 ,ug of L-AmpB per ml, in comparison with equivalent doses of L-AmpB alone.
Antifungal activity. The effects of various doses of AmpB and GMS alone in their free and liposomal forms are shown in Fig. 4 . No difference in K+ release from Candida cells, using free AmpB or L-AmpB, was observed (Fig. 4A) . In contrast, a marked difference in K+ leakage was found when free GMS and L-GMS were compared (Fig. 4B) , suggesting that liposome encapsulation of GMS masks the antifungal activity of the drug, whereas that of L-AmpB is maintained.
The amounts of K+ released from C. albicans, using free drugs alone or in combination, are shown in Fig. 5 . The combination of 0.009 ,ug of AmpB per ml with GMS at increasing concentrations did not potentiate K+ leakage. Nevertheless, the combination of GMS with 0.075 ,ug of free AmpB per ml showed an increase in K+ release as compared with free GMS or AmpB alone. Figure 6 shows the effects of liposomal drugs alone and in combination on C. albicans. Although L-GMS alone had no effect on K+ release, its combination with either 0. earlier studies (6, 12) . Because of its strong hemolytic effects, the use of GMS has been restricted to topical formulations. The variations of toxicity produced by polyene antibiotics alone or in combination might depend on the affinity of drugs for the sterols in RBC and Candida cell membranes (8) . Interestingly, combinations of free drugs protected the integrity of RBC at certain concentrations. Although we do not understand the mechanisms involved that cause this protective effect, we do know that the drugs do not appear to associate (based on spectrophotometric analysis) nor do they precipitate at these concentrations. The liposomal drugs, when combined, enhanced this protective effect significantly, but this is likely due to the presence of increasing concentrations of lipids. Furthermore, as established previously (7, 12) , the antifungal activity of AmpB remained unaltered after liposome encapsulation. We also observed that the combinations of free drugs potentiated the antifungal activity, in comparison with either drug alone. Even though liposome encapsulation of GMS was found to decrease the amount of K+ released from C. albicans, a synergistic antifungal effect was observed when GMS and AmpB were combined in their free and liposomal forms. These results agree with our earlier report (6) that the antifungal activity of GMS is potentiated when combined with low concentrations of AmpB. This effect is probably caused by AmpB, which facilitates GMS crossing through the cell wall to access the plasma membrane.
Even though the mechanism of action for both drugs has been studied extensively (3) , the interaction that improves antifungal activity is still poorly understood. In practical terms, it seems to be a remarkable advantage to obtain a protective effect for mammalian cells along with an improvement in the antimicrobial effect derived from liposomal drug combinations.
Our results suggest that at particular concentrations of drugs the protective effect on RBC and the toxicity to C. albicans would be optimal, for example, a combination of 2.5 jig of AmpB per ml and 12.5 jig of GMS per ml.
Moreover, liposome encapsulation further reduced the toxicity while maintaining the antifungal activity of AmpB; in addition, L-AmpB induced synergistic activity when used in combination with L-GMS. Thus, the combination of LAmpB and L-GMS allowed us to use low concentrations of AmpB, thereby reducing toxicity to RBC and potentiating the antimicrobial activity.
In conclusion, combinations of drugs such as those used in this study may provide an additional adjunct to improved antifungal chemotherapy. The synergistic interaction is common among many drugs and could be a valuable tool to rescue old therapeutic possibilities.
